Cargando…

MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features

The microtubule-associated protein tau (MAPT) H1 haplotype is the strongest genetic risk factor for corticobasal degeneration (CBD). However, the specific H1 subhaplotype association is not well defined, and it is not clear whether any MAPT haplotypes influence severity of tau pathology or clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Valentino, Rebecca R., Koga, Shunsuke, Walton, Ronald L., Soto-Beasley, Alexandra I., Kouri, Naomi, DeTure, Michael A., Murray, Melissa E., Johnson, Patrick W., Petersen, Ronald C., Boeve, Bradley F., Uitti, Ryan J., Wszolek, Zbigniew K., Dickson, Dennis W., Ross, Owen A., Heckman, Michael G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720600/
https://www.ncbi.nlm.nih.gov/pubmed/33287913
http://dx.doi.org/10.1186/s40478-020-01097-z
_version_ 1783619882513858560
author Valentino, Rebecca R.
Koga, Shunsuke
Walton, Ronald L.
Soto-Beasley, Alexandra I.
Kouri, Naomi
DeTure, Michael A.
Murray, Melissa E.
Johnson, Patrick W.
Petersen, Ronald C.
Boeve, Bradley F.
Uitti, Ryan J.
Wszolek, Zbigniew K.
Dickson, Dennis W.
Ross, Owen A.
Heckman, Michael G.
author_facet Valentino, Rebecca R.
Koga, Shunsuke
Walton, Ronald L.
Soto-Beasley, Alexandra I.
Kouri, Naomi
DeTure, Michael A.
Murray, Melissa E.
Johnson, Patrick W.
Petersen, Ronald C.
Boeve, Bradley F.
Uitti, Ryan J.
Wszolek, Zbigniew K.
Dickson, Dennis W.
Ross, Owen A.
Heckman, Michael G.
author_sort Valentino, Rebecca R.
collection PubMed
description The microtubule-associated protein tau (MAPT) H1 haplotype is the strongest genetic risk factor for corticobasal degeneration (CBD). However, the specific H1 subhaplotype association is not well defined, and it is not clear whether any MAPT haplotypes influence severity of tau pathology or clinical presentation in CBD. Therefore, in the current study we examined 230 neuropathologically confirmed CBD cases and 1312 controls in order to assess associations of MAPT haplotypes with risk of CBD, severity of tau pathology (measured as semi-quantitative scores for coiled bodies, neurofibrillary tangles, astrocytic plaques, and neuropil threads), age of CBD onset, and disease duration. After correcting for multiple testing (P < 0.0026 considered as significant), we confirmed the strong association between the MAPT H2 haplotype and decreased risk of CBD (Odds ratio = 0.26, P = 2 × 10(−12)), and also observed a novel association between the H1d subhaplotype and an increased CBD risk (Odds ratio = 1.76, P = 0.002). Additionally, although not statistically significant after correcting for multiple testing, the H1c haplotype was associated with a higher risk of CBD (Odds ratio = 1.49, P = 0.009). No MAPT haplotypes were significantly associated with any tau pathology measures, age of CBD onset, or disease duration. Though replication will be important and there is potential that population stratification could have influenced our findings, these results suggest that several MAPT H1 subhaplotypes are primarily responsible for the strong association between MAPT H1 and risk of CBD, but that H1 subhaplotypes are unlikely to play a major role in driving tau pathology or clinical features. Our findings also indicate that similarities in MAPT haplotype risk-factor profile exist between CBD and the related tauopathy progressive supranuclear palsy, with H2, H1d, and H1c displaying associations with both diseases.
format Online
Article
Text
id pubmed-7720600
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77206002020-12-08 MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features Valentino, Rebecca R. Koga, Shunsuke Walton, Ronald L. Soto-Beasley, Alexandra I. Kouri, Naomi DeTure, Michael A. Murray, Melissa E. Johnson, Patrick W. Petersen, Ronald C. Boeve, Bradley F. Uitti, Ryan J. Wszolek, Zbigniew K. Dickson, Dennis W. Ross, Owen A. Heckman, Michael G. Acta Neuropathol Commun Research The microtubule-associated protein tau (MAPT) H1 haplotype is the strongest genetic risk factor for corticobasal degeneration (CBD). However, the specific H1 subhaplotype association is not well defined, and it is not clear whether any MAPT haplotypes influence severity of tau pathology or clinical presentation in CBD. Therefore, in the current study we examined 230 neuropathologically confirmed CBD cases and 1312 controls in order to assess associations of MAPT haplotypes with risk of CBD, severity of tau pathology (measured as semi-quantitative scores for coiled bodies, neurofibrillary tangles, astrocytic plaques, and neuropil threads), age of CBD onset, and disease duration. After correcting for multiple testing (P < 0.0026 considered as significant), we confirmed the strong association between the MAPT H2 haplotype and decreased risk of CBD (Odds ratio = 0.26, P = 2 × 10(−12)), and also observed a novel association between the H1d subhaplotype and an increased CBD risk (Odds ratio = 1.76, P = 0.002). Additionally, although not statistically significant after correcting for multiple testing, the H1c haplotype was associated with a higher risk of CBD (Odds ratio = 1.49, P = 0.009). No MAPT haplotypes were significantly associated with any tau pathology measures, age of CBD onset, or disease duration. Though replication will be important and there is potential that population stratification could have influenced our findings, these results suggest that several MAPT H1 subhaplotypes are primarily responsible for the strong association between MAPT H1 and risk of CBD, but that H1 subhaplotypes are unlikely to play a major role in driving tau pathology or clinical features. Our findings also indicate that similarities in MAPT haplotype risk-factor profile exist between CBD and the related tauopathy progressive supranuclear palsy, with H2, H1d, and H1c displaying associations with both diseases. BioMed Central 2020-12-07 /pmc/articles/PMC7720600/ /pubmed/33287913 http://dx.doi.org/10.1186/s40478-020-01097-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Valentino, Rebecca R.
Koga, Shunsuke
Walton, Ronald L.
Soto-Beasley, Alexandra I.
Kouri, Naomi
DeTure, Michael A.
Murray, Melissa E.
Johnson, Patrick W.
Petersen, Ronald C.
Boeve, Bradley F.
Uitti, Ryan J.
Wszolek, Zbigniew K.
Dickson, Dennis W.
Ross, Owen A.
Heckman, Michael G.
MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features
title MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features
title_full MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features
title_fullStr MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features
title_full_unstemmed MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features
title_short MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features
title_sort mapt subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720600/
https://www.ncbi.nlm.nih.gov/pubmed/33287913
http://dx.doi.org/10.1186/s40478-020-01097-z
work_keys_str_mv AT valentinorebeccar maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures
AT kogashunsuke maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures
AT waltonronaldl maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures
AT sotobeasleyalexandrai maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures
AT kourinaomi maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures
AT deturemichaela maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures
AT murraymelissae maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures
AT johnsonpatrickw maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures
AT petersenronaldc maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures
AT boevebradleyf maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures
AT uittiryanj maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures
AT wszolekzbigniewk maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures
AT dicksondennisw maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures
AT rossowena maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures
AT heckmanmichaelg maptsubhaplotypesincorticobasaldegenerationassessingassociationswithdiseaseriskseverityoftaupathologyandclinicalfeatures